The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S1-S3 , October 2007

Introduction

  • Kenneth V.I. Rolston, MD

      Affiliations

    • M. D. Anderson Cancer Center, University of Texas, Houston, Texas, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Kenneth V. I. Rolston, MD, M. D. Anderson Cancer Center, University of Texas, 4032 Coleridge, Houston, Texas 77005.
    • ,
  • John Segreti, MD

      Affiliations

    • Rush University Medical Center, Chicago, Illinois, USA

References 

  1. Bad Bugs, No Drugs. Infectious Diseases Society of America, July 2004. Available at: http://www.idsociety.org/pa/IDSA_ Paper4_ final_ web.pdf. Accessed August 20, 2007.
  2. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–668
  3. Moellering RC. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(suppl 1):S3–S4
  4. Kapadia M, Coyle E, Prince R, Rolston K. Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at the 45th Annual Meeting of Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) In: Washington DC: Ameican Society for Microbiology; 2005;p. 168;Abstract E–807.
  5. Safdar A, Rolston KV. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer. 2006;106:1815–1820
  6. Fowler VG, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus: infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis. 2004;190:1140–1149
  7. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus—an antibiotic enters obsolescence. Clin Infect Dis. 2007;44:1543–1548
  8. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994–1000
  9. Arbeit RD, Maki D, Tally FP, Campanaro E Eisenstein BI, and the Daptomycin 98–01 and 99–01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681
  10. Zyvox. [prescribing information] New York, NY: Pfizer Inc; 2007;
  11. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40:374–380
  12. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159–168
  13. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50:1599–1602

 Statement of conflict of interest: Dr. Kenneth V. I. Rolston, MD, and Dr. John Segreti, MD report no conflict of interest with the sponsor of this supplement article or products discussed in this article.

PII: S0002-9343(07)00657-2

doi: 10.1016/j.amjmed.2007.07.007

The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S1-S3 , October 2007

Article Tools